Valuation: Abpro Corporation

Market Cap 23.58L 20.57L 19.42L 17.63L 33.04L 23Cr 33.18L 2.33Cr 89.76L 12Cr 88.59L 86.63L 37Cr P/E 2024
-2.41x
P/E 2025 -3.27x
Enterprise Value 24.38L 21.26L 20.08L 18.23L 34.16L 23Cr 34.3L 2.4Cr 92.81L 12Cr 91.6L 89.57L 38Cr EV / Sales 2024
497x
EV / Sales 2025 -
Free-Float
83.91%
Yield 2024 *
-
Yield 2025 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 23.58L
+0.11%+2.71%+0.33%+28.59% 4.62TCr
-1.11%+1.80%+40.11%+27.29% 4.43TCr
-3.27%-7.16%+318.35%+511.64% 4.22TCr
-0.99%+0.98%+2.04%+67.48% 4.02TCr
-0.50%-0.77%+11.86%+40.41% 2.98TCr
-0.60%+3.97%+21.69%+123.66% 1.72TCr
-0.06%-9.69% - - 1.57TCr
-0.57%+8.12%+22.15%+38.93% 1.53TCr
-2.90%-2.62%-8.11%-37.31% 1.31TCr
Average -1.01%+1.67%+51.05%+100.09% 2.93TCr
Weighted average by Cap. -1.14%+1.63%+65.53%+121.92%

Financials

2024 2025
Net sales 2L 2L 2L 1L 3L 1.76Cr 3L 18.05L 7L 89.28L 7L 7L 2.87Cr -
Net income -72.32L -63.06L -59.55L -54.07L -1.01Cr -69Cr -1.02Cr -7.13Cr -2.75Cr -35Cr -2.72Cr -2.66Cr -113.52Cr -28.92L -25.22L -23.81L -21.62L -40.51L -28Cr -40.68L -2.85Cr -1.1Cr -14Cr -1.09Cr -1.06Cr -45Cr
Net Debt 5L 4L 4L 4L 7L 4.59Cr 7L 47.14L 18.19L 2.33Cr 17.96L 17.56L 7.5Cr 80T 69.76T 65.87T 59.81T 1L 76.76L 1L 8L 3L 39.03L 3L 3L 1.26Cr
Logo Abpro Corporation
Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!